Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:231
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2019  |  Volume : 4  |  Issue : 2  |  Page : 208-213

Investigation of HLA-DRB1*15:03 and HLA-DRB1*09:01 alleles to determine predisposition to development of ABO antibodies (Anti-A and Anti-B) amongst blood donors of type “O” in Southern Iran


1 Department of Biology, Islamic Azad University, Arsanjan Branch, Arsanjan, Iran
2 Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Correspondence Address:
Dr. Ali Akbar Pourfathollah
Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/GJTM.GJTM_56_19

Rights and Permissions

Introduction: Agglutination in red blood cells can be associated with a number of complications. These complications are related to the amount of antibody titer produced. Some genetic factors, such as HLA-DRB1*15:03 and HLA-DRB1*09:01 alleles, are involved in the production of antibody titers. Aims and Objectives: The aim of this study was to investigate the causative allele of the high and dangerous titer antibodies (anti-A and anti-B) among blood donors in Bandar Abbas. Methods: Antibody A and B levels were measured by titration on 121 serum samples of blood type O donors in 2 incubations at room temperature and anti-human globulin tube method. Titers higher than 512 and the same number of participants with a titer of <64 were selected and whether or not genotypes 901 and 1503 were found. After titration, sample DNAs were extracted, and then, amplification-refractory mutation system–polymerase chain reaction was used to determine allelic polymorphism. Results: The antibody titer was found to be elevated in this study, but there was no significant relationship between the presence or absence of genotype 901 (HLA-DRB1*9:01) and genotype 1503 (HLA-DRB1*15:03) and the high titer of anti-A and anti-B antibodies. Discussion and Conclusion: Finally, studies have shown that a critical titer should be determined for antibodies to the ABO blood system in order to provide blood transfusion safety. However, the higher the titers of anti-A and anti-B, the safety of transfusion medicine is also provided.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed38    
    Printed2    
    Emailed0    
    PDF Downloaded33    
    Comments [Add]    

Recommend this journal